A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.
1438-0001
Phase 1 other active
Quick answer
A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3. for Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3 is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3
- Phase
- Phase 1
- Modality
- other
- Status
- active